



1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of :
Donald L. Durden : Examiner: Not Yet Assigned
Serial No. 10/770,725 : Group Art Unit: 1641
Filed: February 3, 2004 :
For: "COMPOSITIONS AND METHODS:
FOR IDENTIFYING AGENTS :
WHICH MODULATE PTEN :
FUNCTION AND PI-3 KINASE :
PATHWAYS" :

Certificate of Mailing Under 37 CFR §1.8(a)

I hereby certify that this Correspondence is being deposited on August 19, 2004 with the United States Postal Service as first-class mail in an envelope properly addressed to COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450.

Janice M. Nightlinger
Janice M. Nightlinger

REQUEST FOR LISTING OF REFERENCES

Applicant in the above-identified application is submitting herewith a Form PTO-1449 listing references that were considered and made of record in connection with Applicants' parent U.S. Application No. 09/870,379, filed May 30, 2001.


It is respectfully requested that the references included in the Form PTO-1449 submitted herewith be listed on the face of the patent granted on the above-identified application, in accordance with the following provisions of §609 of the Manual of Patent Examining Procedure:

[T]he examiner will consider information which has been considered by the Office in a parent application when examining (A) a continuation application filed under 37 CFR 1.53(b) or filed under former 37 CFR 160, (B) a divisional application filed under 37 CFR 1.53(b) or filed under form 37 CFR 1.60, or (C) a continuation-in-part application filed under 37 CFR 1.53(b). Such information need not be resubmitted in the continuing application unless applicant desires the information to be printed on the patent.

In the event any fee is due in connection with the consideration of this request, the Commissioner is authorized to charge any such fee to the account of the undersigned attorneys, Deposit Account No. 04-1406.


Respectfully submitted,

DANN DORFMAN HERRELL and
SKILLMAN, P.C.
Attorneys for Applicant

By 
Kathleen D. Rigaut, Ph.D., J.D.
Registration No. 43,047

KDR:jmn
Enclosure

Telephone: 215-563-4100
Facsimile: 215-563-4044
Customer No. 000110

	<i>Complete if known</i>	
	Application Number: 09/870379	
	Filing Date: May 30, 2001	
	First Named Inventor: Donald L. Durden	
	Group Art Unit: 1642	
	Examiner Name: Yu, Misook	
SHEET 1 OF 1		Attorney Docket Number: 1857-P02575US1

UNITED STATES PATENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	6020199	02-01-2000	Monia, et al.

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

OTHER PRIOR ART - NON-PATENT DOCUMENTS		
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	LI, DA-MING, et al., "PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G ₁ cell cycle arrest in human glioblastoma cells"; Proc. Natl. Acad. Sci. USA, 95:15406-15411 (1998)
	C2	LI, LIWU, et al., "A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast"; J. Biological Chemistry, 272: 29403-29406 (1997)
	C3	LI, JING, et al., "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer"; Science 275: 1943-1947 (1997)
	C4	HUANG, HE, et al., "PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development"; Development 126: 5365-5372 (1999)
	C5	LEE, JIE-OH, et al., "Crystal Structure of the PTEN Tumor Suppressor: Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association"; Cell, 99: 323-334 (1999)
	C6	SUN, HONG, et al., "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5 -trisphosphate and Akt/protein kinase B signaling pathway"; Proc. Natl. Acad. Sci. USA 96: 6199-6204 (1999)
	C7	GIRI, D., et al., "Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma"; PubMed, Hum. Pathol. 30:419-24 [abstract] (1999)

EXAMINER'S SIGNATURE		DATE CONSIDERED	
----------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of :
Donald L. Durden : Examiner: Not Yet Assigned
Serial No. 10/770,725 : Group Art Unit: 1641
Filed: February 3, 2004 :
For: "COMPOSITIONS AND METHODS:
FOR IDENTIFYING AGENTS :
WHICH MODULATE PTEN :
FUNCTION AND PI-3 KINASE :
PATHWAYS" :

Certificate of Mailing Under 37 CFR §1.8(a)

I hereby certify that this Correspondence is being deposited on
August 19, 2004 with the United States Postal Service as first-class mail
in an envelope properly addressed to COMMISSIONER FOR PATENTS, P.O. Box
1450, Alexandria, VA 22313-1450.

Janice M. Nightlinger
Janice M. Nightlinger

REQUEST FOR LISTING OF REFERENCES

Applicant in the above-identified application is
submitting herewith a Form PTO-1449 listing references that
were considered and made of record in connection with
Applicants' parent U.S. Application No. 09/870,379, filed
May 30, 2001.


It is respectfully requested that the references included
in the Form PTO-1449 submitted herewith be listed on the face
of the patent granted on the above-identified application, in
accordance with the following provisions of §609 of the Manual
of Patent Examining Procedure:

[T]he examiner will consider information which has
been considered by the Office in a parent application
when examining (A) a continuation application filed
under 37 CFR 1.53(b) or filed under former 37 CFR
160, (B) a divisional application filed under 37 CFR
1.53(b) or filed under form 37 CFR 1.60, or (C) a
continuation-in-part application filed under 37 CFR
1.53(b). Such information need not be resubmitted in
the continuing application unless applicant desires
the information to be printed on the patent.

In the event any fee is due in connection with the consideration of this request, the Commissioner is authorized to charge any such fee to the account of the undersigned attorneys, Deposit Account No. 04-1406.


Respectfully submitted,

DANN DORFMAN HERRELL and
SKILLMAN, P.C.
Attorneys for Applicant

By 
Kathleen D. Rigaut, Ph.D., J.D.
Registration No. 43,047

KDR:jmn
Enclosure

Telephone: 215-563-4100
Facsimile: 215-563-4044
Customer No. 000110

	<i>Complete if known</i>	
	Application Number: 09/870379	
	Filing Date: May 30, 2001	
	First Named Inventor: Donald L. Durden	
	Group Art Unit: 1642	
	Examiner Name: Yu, Misook	
SHEET 1 OF 1		Attorney Docket Number: 1857-P02575US1

UNITED STATES PATENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	6020199	02-01-2000	Monia, et al.

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

OTHER PRIOR ART - NON-PATENT DOCUMENTS		
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	LI, DA-MING, et al., "PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G ₁ cell cycle arrest in human glioblastoma cells"; Proc. Natl. Acad. Sci. USA, 95:15406-15411 (1998)
	C2	LI, LIWU, et al., "A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast"; J. Biological Chemistry, 272: 29403-29406 (1997)
	C3	LI, JING, et al., "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer"; Science 275: 1943-1947 (1997)
	C4	HUANG, HE, et al., "PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development"; Development 126: 5365-5372 (1999)
	C5	LEE, JIE-OH, et al., "Crystal Structure of the PTEN Tumor Suppressor: Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association"; Cell, 99: 323-334 (1999)
	C6	SUN, HONG, et al., "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5 -trisphosphate and Akt/protein kinase B signaling pathway"; Proc. Natl. Acad. Sci. USA 96: 6199-6204 (1999)
	C7	GIRI, D., et al., "Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma"; PubMed, Hum. Pathol. 30:419-24 [abstract] (1999)

EXAMINER'S SIGNATURE		DATE CONSIDERED	
----------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.